Targeting Aging-Related Diseases with Underlying Mitochondrial Dysfunction
Mitochondrion Application Biomedicine Inc. (MAB) is an emerging leader in the worldwide development of regenerative medicine on mitochondrial technology. MAB has focused on mitochondrial R&D and application technology platforms since 2014 and the first company that develops Mitochondrial Reconstruction Therapy (MRT). MAB operating bases are in Taiwan, Beijing, Shenzhen, and Hong Kong, and so on.
The population of aging around world is increasing dramatically. Mitochondrial dysfunction is closely associated with the development of aging and degenerative diseases (such as Parkinson's disease and Alzheimer's disease, etc.). Because impaired mitochondria will be insufficient to energy supply and trigger reactive oxygen species induction, and even induce cells to enter apoptosis or autophagy, which will lead to disease.
Currently, a number of product lines have been developed, including MitoCell (stem cells), MitoBio (Mitochondria), MAKcell (immune cells), MitoScan (functional mitochondria assay), Dynamito MAPEs (mitochondria-improvement ingredient), MitoFood (food supplements), and Stemoto (stem cell culturing medium), etc. MitoCell, MitoBio, MAKCell are preparing to enter the next stage of clinical development, and other products or testing services are marketed in the fields of preventive healthcare supplements, aesthetic medicine, stem cell culture, health examination, and mitochondrial metabolomics. These products or services have been demonstrated to be safe, effective, and accurate in preliminary studies.